{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066419","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.033521+00:00","generated_at":"2026-05-22T05:25:37.113353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PepGen Q1 2025 net loss $30.2M; DM1 splicing correction 29.1% at 10 mg/kg","bullets":["Net loss $30.2M ($0.92/share) in Q1 2025 vs. $18.0M ($0.63/share) in Q1 2024.","Cash and marketable securities $97.8M as of March 31, 2025; runway at least 12 months.","Positive DM1 data: mean splicing correction of 29.1% 28 days after single 10 mg/kg dose of PGN-EDODM1.","CONNECT1-EDO51 10 mg/kg dystrophin data expected Q3 2025; CONNECT2 trial voluntarily paused.","Board added Lisa Wyman and Mitchell H. Finer, PhD in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066419","json":"https://secwatch.observer/filing/0000950170-25-066419.json","markdown":"https://secwatch.observer/filing/0000950170-25-066419.md","text":"https://secwatch.observer/filing/0000950170-25-066419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/0000950170-25-066419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017025066419/pepg-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:25:37.113353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}